A Phase 3 interventional study of Roflumilast and Placebo in COPD and Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 20 sites in 5 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-11-29.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 16th largest by enrollment, is one of 4 that started in 2012, is one of 16 in phase 3, and was the 18th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 17 · Phase 4 8
First in 2003; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 158 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 154 across the 32 interventional studies. Of the 30 that completed or were terminated, 17 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 32 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 91st largest by enrollment of the 194 interventional ones that give a count, is one of 18 that started in 2012, is one of 76 in phase 3, and was the 116th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing roflumilast in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07795086Sidra AzizComparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The objective of the Biopsy trial is to investigate the effect of roflumilast 500 µg tablets once daily versus placebo on inflammation parameters in bronchial biopsy tissue specimen and additional in sputum and blood serum. Also data on safety status will be obtained.
Patients to be included required to have moderate to severe COPD associated with chronic bronchitis. The total duration of this randomized, multicentre, phase III trial is 24 weeks maximum.
This was a multicenter, double-blind, randomized, parallel group, phase 3 study. Patients included had a history of COPD (GOLD stage II-III, in Germany stage II only) with chronic productive cough.
There were 2 parallel treatment arms (placebo and roflumilast 500 μg once daily). A 1 to 1 randomization scheme was used, that is, patients were allocated to roflumilast 500 μg or placebo in equal proportions. Randomization was stratified by concomitant LABA use.
The total duration of this study was 24 weeks maximum per patient. The study consisted of the following periods:
An additional visit (V3) within 2 weeks after bronchoscopy/bronchial biopsy was performed purely as a safety visit. The exact timing of this safety visit was to be determined by the investigator. Safety follow-up. All AEs were followed up to 30 days after the double-blind treatment period. An additional safety visit, V7, was scheduled within 2 weeks after the second bronchoscopy. The exact timing of the safety visit was to be determined by the investigator.
Patients were required not to take any food or drink overnight for at least 8 hours prior to returning to the study center for each visit. Patients were also asked to avoid strenuous exercise for 8 hours prior to each study visit and to avoid smoking for 4 hours prior to each study visit.
For visits where patients did not undergo blood collections or biopsies, the fasting requirement was only mandated if clinically indicated, per investigator judgment.
Major Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500 μg tablet, once daily, oral administration in the morning after breakfast
Drug: Roflumilast
tablet, once daily, oral administration in the morning after breakfast
Drug: Placebo
500 μg tablet, once daily, oral administration in the morning after breakfast
Also known as: Daxas
tablet, once daily, oral administration in the morning after breakfast
Also known as: Placebo to Roflumilast
Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue.
Time frame: 16 weeks
Change in Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue
Time frame: Baseline to 16 weeks
CD68+ Count in Biopsied Material (Submucosa)
Time frame: 16 weeks
CD68+ Cell Count in Biopsied Material (Submucosa): Poisson Regression (Ratio)
CD68+ Cell Count in Biopsied Material (submucosa): Poisson regression (ratio). Clarification: Measure type described as "Number" refers to "Risk of each treatment group". It is not possible to select "risk" from this template so "number" was selected instead. This issue applies to similar variables reporting poisson regression.
Time frame: 16 weeks
Change From V2 to V6 in CD68+ Cell Count (Cells/mm^2) in Biopsied Material (Submucosa) (ITT)
Time frame: Baseline and 16 weeks
CD4+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model
CD4+ Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type "Number" refers to "Risk of each treatment group".
Time frame: 16 weeks
CD45+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model
CD45+ Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type "Number" refers to "treatment risk"
Time frame: 16 weeks
Neutrophils Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model
Neutrophils Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type "Number" refers to "Treatment risk"
Time frame: Baseline to 14 weeks
CD8+ Cell Count in Biopsied Material (Bronchial Epithelium): Poisson Regression Model
CD8+ Cell Count in biopsied material (Bronchial Epithelium): poisson regression model. Clarification: Measure Type "Number" refers to "Treatment risk"
Time frame: 16 weeks
CD68+ Cell Count in Biopsied Material (Bronchial Epithelium):Poisson Regression Model
CD68+ Cell Count in biopsied material (Bronchial Epithelium):poisson regression model. Clarification: Measure type "Number" refers to "Treatment Risk"
Time frame: 16 weeks
Change From V1 to V5 in Absolute Cell Count in Induced Sputum (10^6 Neutrophils/mL): Between-Treatment Difference
Time frame: Baseline to 14 weeks
Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Macrophages/mL): Between-Treatment Difference
Time frame: Baseline to 14 weeks
Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Eosinophils/mL): Between-Treatment Difference
Time frame: Baseline to 14 weeks
Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Lymphocytes/mL): Between-Treatment Difference
Time frame: BAseline to 14 weeks
Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Neutrophils/mL)
Time frame: Baseline to 14 weeks
Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Macrophages/mL)
Time frame: Baseline to 14 weeks
Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Eosinophils/mL)
Time frame: Baseline to 14 weeks
Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Lymphocytes)/mL)
Time frame: Baseline to 14 weeks
Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (Alfa- 2-Macroglobulin (µg/mL))
Time frame: Baseline to 14 weeks
Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (IL-8 (pg/mL))
Time frame: Baseline to 14 weeks
Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (MMP Type 9 (ng/mL))
Time frame: Baseline to 14 weeks
Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (MCP-1 (pg/mL))
Time frame: Baseline to 14 weeks
Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (TIMP-1 (ng/mL))
Time frame: Baseline to 14 weeks
Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (VEGF (pg/mL))
Time frame: Baseline to 14 weeks
Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (Alfa-2-Macroglobulin (µg/mL))
Time frame: Baseline to 14 weeks
Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (IL-8 (pg/mL))
Time frame: Baseline to 14 weeks
Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (MMP Type 9 (ng/mL))
Time frame: Baseline to 14 weeks
Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (MCP-1(pg/mL))
Time frame: Baseline to 14 weeks
Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (TIMP-1(ng/mL))
Time frame: Baseline to 14 weeks
Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (VEGF(pg/mL))
Time frame: Baseline to 14 weeks
Change From Baseline in Lung Function Variables: Between-Treatment Differences (FAS) (FEV1 (L))
Time frame: Baseline to 16 weeks
Change From Baseline in Lung Function Variables: Between-Treatment Differences (FAS) (FVC (L))
Time frame: Baseline to 16 weeks
Wicoxon Signed-rank Test for Change From V2 to V6 in Post-bronchodilator FEV1/FVC
Wilcoxon test is a non-parametric test to evaluate differences among treatments in the variable that is being reported here. The data reported in the outcome measure data table are hodges Lehmann estimate of change from baseline in FEV1/FVC ratio.
Time frame: Baseline to 16 weeks
| Milestone | R500 | Placebo |
|---|---|---|
| Started | 79 | 79 |
| Completed | 76 | 73 |
| Not completed | 3 | 6 |
| CD8+ cells count | R500 | Placebo |
|---|---|---|
| Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue. | 442.4 ± 312.74 | 427.1 ± 261.42 |
| cells/mm^2 | R500 | Placebo |
|---|---|---|
| Change in Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue | 13.4 ± 302.69 | 29.4 ± 298.88 |
| CD68+ Count | R500 | Placebo |
|---|---|---|
| CD68+ Count in Biopsied Material (Submucosa) | 149.1 ± 113.91 | 124.4 ± 93.15 |
CD68+ Cell Count in Biopsied Material (submucosa): Poisson regression (ratio). Clarification: Measure type described as "Number" refers to "Risk of each treatment group". It is not possible to select "risk" from this template so "number" was selected instead. This issue applies to similar variables reporting poisson regression.
| CD68+ Cell Count | R500 | Placebo |
|---|---|---|
| CD68+ Cell Count in Biopsied Material (Submucosa): Poisson Regression (Ratio) | 126.8 ± NA | 121.6 ± NA |
| CD68+ Cell Count (cells/mm^2) | R500 | Placebo |
|---|---|---|
| Change From V2 to V6 in CD68+ Cell Count (Cells/mm^2) in Biopsied Material (Submucosa) (ITT) | 6.1 ± 10.99 | -5.3 ± 11.05 |
CD4+ Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type "Number" refers to "Risk of each treatment group".
| CD4+ Cell Counts | R500 | Placebo |
|---|---|---|
| CD4+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model | 304.6 ± NA | 255.0 ± NA |
CD45+ Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type "Number" refers to "treatment risk"
| CD45+ Cell Counts | R500 | Placebo |
|---|---|---|
| CD45+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model | 818.4 ± NA | 960.3 ± NA |
Neutrophils Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type "Number" refers to "Treatment risk"
| Neutrophils Cell Counts | R500 | Placebo |
|---|---|---|
| Neutrophils Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model | 118.6 ± NA | 127.7 ± NA |
CD8+ Cell Count in biopsied material (Bronchial Epithelium): poisson regression model. Clarification: Measure Type "Number" refers to "Treatment risk"
| CD8+ Cell Count | R500 | Placebo |
|---|---|---|
| CD8+ Cell Count in Biopsied Material (Bronchial Epithelium): Poisson Regression Model | 422.1 ± NA | 505.3 ± NA |
CD68+ Cell Count in biopsied material (Bronchial Epithelium):poisson regression model. Clarification: Measure type "Number" refers to "Treatment Risk"
| CD68+ Cell Count | R500 | Placebo |
|---|---|---|
| CD68+ Cell Count in Biopsied Material (Bronchial Epithelium):Poisson Regression Model | 76.3 ± NA | 93.1 ± NA |
| 10^6 neutrophils/mL | R500 | Placebo |
|---|---|---|
| Change From V1 to V5 in Absolute Cell Count in Induced Sputum (10^6 Neutrophils/mL): Between-Treatment Difference | 1.7181 ± 1.64471 | 0.0827 ± 1.61220 |
| 10^6 macrophages/mL | R500 | Placebo |
|---|---|---|
| Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Macrophages/mL): Between-Treatment Difference | 0.1017 ± 0.23396 | -0.3710 ± 0.22970 |
| 10^6 eosinophils/mL | R500 | Placebo |
|---|---|---|
| Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Eosinophils/mL): Between-Treatment Difference | -0.0986 ± 0.02639 | -0.0360 ± 0.02585 |
| 10^6 lymphocytes/mL | R500 | Placebo |
|---|---|---|
| Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Lymphocytes/mL): Between-Treatment Difference | -0.0167 ± 0.01167 | -0.0060 ± 0.01141 |
| 10^6 neutrophils/mL | R500 | Placebo |
|---|---|---|
| Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Neutrophils/mL) | 2.527 ± 2.3571 | 0.382 ± 2.3535 |
| 10^6 macrophages/mL | R500 | Placebo |
|---|---|---|
| Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Macrophages/mL) | 0.315 ± 2.1328 | -0.826 ± 2.1316 |
| 10^6 eosinophils/m | R500 | Placebo |
|---|---|---|
| Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Eosinophils/mL) | -1.826 ± 0.5214 | -0.041 ± 0.5200 |
| 10^6 lymphocytes)/mL | R500 | Placebo |
|---|---|---|
| Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Lymphocytes)/mL) | -0.137 ± 0.1332 | -0.086 ± 1.329 |
| µg/mL | R500 | Placebo |
|---|---|---|
| Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (Alfa- 2-Macroglobulin (µg/mL)) | -0.32 ± 0.730 | -0.48 ± 0.700 |
| pg/mL | R500 | Placebo |
|---|---|---|
| Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (IL-8 (pg/mL)) | -827.3 ± 1995.79 | -1538.4 ± 1941.08 |
| ng/mL | R500 | Placebo |
|---|---|---|
| Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (MMP Type 9 (ng/mL)) | 80.1 ± 57.07 | -8.4 ± 55.44 |
| pg/mL | R500 | Placebo |
|---|---|---|
| Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (MCP-1 (pg/mL)) | -95.2 ± 49.23 | -69.3 ± 46.93 |
| ng/mL | R500 | Placebo |
|---|---|---|
| Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (TIMP-1 (ng/mL)) | 25.87 ± 13.085 | -1.92 ± 12.551 |
| pg/mL | R500 | Placebo |
|---|---|---|
| Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (VEGF (pg/mL)) | 253.1 ± 89.46 | -43.7 ± 86.84 |
| µg/mL | R500 | Placebo |
|---|---|---|
| Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (Alfa-2-Macroglobulin (µg/mL)) | -0.05 ± 0.061 | -0.05 ± 0.062 |
| pg/mL | R500 | Placebo |
|---|---|---|
| Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (IL-8 (pg/mL)) | -4.48 ± 0.929 | -3.92 ± 0.945 |
| ng/mL | R500 | Placebo |
|---|---|---|
| Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (MMP Type 9 (ng/mL)) | 0.8 ± 0.78 | -1.0 ± 0.79 |
| pg/mL | R500 | Placebo |
|---|---|---|
| Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (MCP-1(pg/mL)) | -24.8 ± 11.0 | -23.4 ± 11.21 |
| ng/mL | R500 | Placebo |
|---|---|---|
| Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (TIMP-1(ng/mL)) | 2.7 ± 3.19 | -7.5 ± 3.25 |
| pg/mL | R500 | Placebo |
|---|---|---|
| Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (VEGF(pg/mL)) | 11.3 ± 12.80 | -21.5 ± 13.08 |
| L | R500 | Placebo |
|---|---|---|
| Change From Baseline in Lung Function Variables: Between-Treatment Differences (FAS) (FEV1 (L)) | 0.028 ± 0.0212 | -0.035 ± 0.0212 |
| L | R500 | Placebo |
|---|---|---|
| Change From Baseline in Lung Function Variables: Between-Treatment Differences (FAS) (FVC (L)) | 0.031 ± 0.0391 | -0.033 ± 0.391 |
Wilcoxon test is a non-parametric test to evaluate differences among treatments in the variable that is being reported here. The data reported in the outcome measure data table are hodges Lehmann estimate of change from baseline in FEV1/FVC ratio.
| ratio | R500 | Placebo |
|---|---|---|
| Wicoxon Signed-rank Test for Change From V2 to V6 in Post-bronchodilator FEV1/FVC | 0.5 (0 to 1) | -0.5 (-1 to 0.5) |
Collected over 16 weeks. Non-serious events are listed at a 0.02% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| R500 | — | 8/79 (10.1%) | 69/79 (87.3%) |
| Placebo | — | 5/79 (6.3%) | 57/79 (72.2%) |
| Event | R500 | Placebo |
|---|---|---|
| COPDRespiratory, thoracic and mediastinal disorders | 3/79 | 1/79 |
| HydroceleCongenital, familial and genetic disorders | 0/79 | 1/79 |
| DyspepsiaGastrointestinal disorders | 1/79 | 0/79 |
| Incarcerated herniaGeneral disorders | 0/79 | 1/79 |
| DiverticulitisInfections and infestations | 1/79 | 0/79 |
| PneumoniaInfections and infestations | 0/79 | 1/79 |
| Influenza A virus test positiveInvestigations | 1/79 | 0/79 |
| Synovial cystMusculoskeletal and connective tissue disorders | 1/79 | 0/79 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/79 | 0/79 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/79 | 0/79 |
| Event | R500 | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 13/79 | 12/79 |
| COPDRespiratory, thoracic and mediastinal disorders | 9/79 | 12/79 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/79 | 12/79 |
| DiarrhoeaGastrointestinal disorders | 11/79 | 4/79 |
| InsomniaPsychiatric disorders | 7/79 | 2/79 |
| NauseaGastrointestinal disorders | 6/79 | 1/79 |
| Weight decreasedInvestigations | 6/79 | 2/79 |
| VomitingGastrointestinal disorders | 5/79 | 2/79 |
| Back painMusculoskeletal and connective tissue disorders | 5/79 | 2/79 |
| HaedacheNervous system disorders | 4/79 | 3/79 |
| Age, Continuous(Years) | R500 | Placebo | Total |
|---|---|---|---|
| Mean | 64 ± 8.23 | 62.5 ± 8.43 | 63.2 ± 8.34 |
| Age, Customized(Participants) | R500 | Placebo | Total |
|---|---|---|---|
| Between 18 and 65 years | 37 | 46 | 83 |
| >=65 years | 42 | 33 | 75 |
| Sex: Female, Male(Participants) | R500 | Placebo | Total |
|---|---|---|---|
| Female | 19 | 18 | 37 |
| Male | 60 | 61 | 121 |
| Race/Ethnicity, Customized(Participants) | R500 | Placebo | Total |
|---|---|---|---|
| Asian | 0 | 1 | 1 |
| Black or African American | 1 | 0 | 1 |
| White | 77 | 77 | 154 |
| Other | 1 | 1 | 2 |
| Region of Enrollment(Participants) | R500 | Placebo | Total |
|---|---|---|---|
| Europe | 79 | 79 | 158 |
Ran from Feb 2012 to primary completion in Feb 2016, 48 months.
Results were first posted in Nov 2019, 3 years 9 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 48 months is above that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Pulmonary Disease, Chronic Obstructive →